The investment sets the stage for accelerated growth and value creation for Vetigenics. The funds will be used to advance clinical-stage programs toward pivotal trials, accelerate exciting preclinical candidates, and scale up operations and manufacturing. "The funding underscores the confidence our investor partners have in our ability to achieve significant progress in a capital-efficient manner," says Adriann Sax, President, CEO and co-founder of Vetigenics. "They share our belief in the potential of biologics to treat a variety of diseases in pets and the unique capabilities of Vetigenics to stay ahead in this evolving field."